Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SNF472 for Wound Healing in Uremic Calciphylaxis
2015-004313-25Phase 2Completed
- Sponsor
- Sanifit Therapeutics
- Start
- Jan 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SNF472 in calciphylaxis (CUA), sponsored by Sanifit Therapeutics. Primary endpoint: Primary lesion wound healing (imaging-based). Started Jan 2016; status: completed.
02
Drugs
SNF472
03
Conditions
calciphylaxis (CUA)
Beyond the preview
Go deeper on 2015-004313-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004313-25.